Aerie Pharmaceuticals announced that the U.S. FDA has reviewed the Investigational New Drug Application for AR-13503 and it is now in effect, allowing Aerie to initiate human studies in the treatment of neovascular age-related macular degeneration and diabetic macular edema. The IND was submitted in March. Aerie expects to initiate a first-in-human clinical study later in the second quarter.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.